Global Idiopathic Pulmonary Fibrosis (IPF) Pipeline Analysis Report 2017: 97 Product Candidates - 1 in Phase III, 15 in Phase II, 12 are in Phase I, 39 are in Pre-clinical and 7 in Discovery Stage

Dublin, March 28, 2017 -- Research and Markets has announced the addition of the "Global Idiopathic Pulmonary Fibrosis (IPF) Pipeline Analysis, 2016" report to their offering.

The IPF pipeline is very strong with a total of 97 drug candidates. Pharma giant such as Asahi Kasei Corporation, Merck & Co., Inc., Biogen and Sanofi are involved in the development of the IPF therapeutics. The IPF pipeline comprised of 97 product candidates, of which one is in Phase III stage, 15 are in Phase II stage, 12 are in Phase I stage, 39 are in Pre-clinical stage, and seven are in discovery stage.

SM04646 is under Phase I stage of development by Samumed, LLC for the treatment of IPF. The drug candidate is a small molecule that acts as Wnt pathway modulator. Samumed is using the technology for development of small molecule that modulate Wnt pathway. The technology is not a stem cell therapy, instead focusing on the modulation of the Wnt pathway that recovers and restores the health of diseased tissues and presents significant opportunities in regenerative therapeutics.

Several companies are involved in IPF with their products in different phases. The only Phase III IPF drug candidate is being developed by Asahi Kasei Pharma Corporation.

The IPF pipeline drug candidates of Merck & Co., Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG and FibroGen, Inc. are in Phase II stage of development.

Bristol-Myers Squibb Company is also having its IPF pipeline drug candidates in different clinical stages, including two drugs in Phase II and one drug in Phase I.

Key Topics Covered:

1. Research Scope And Methodology
1.1 Research Scope
1.2 Research Methodology And Sources

2. Executive Summary
2.1 Key Findings
2.2 Research Summary

3. Pipeline Outlook
3.1 Overview
3.2 Idiopathic Pulmonary Fibrosis Pipeline Analysis

4. Global Idiopathic Pulmonary Fibrosis (Ipf) Pipeline Analysis By Phase (2016)
4.1 Phase II
4.1.1 Thrombomodulin Alfa
4.1.1.1 Clinical Trials
4.2 Phase II
4.2.1 Lebrikizumab
4.2.2 Tipelukast
4.2.3 Kd025
4.2.4 Mk-7624
4.2.5 Glpg1690
4.2.6 Lt-1001
4.2.7 Bg00011
4.2.8 Bms-986020
4.2.9 Lt-1002
4.2.10 Pamrevlumab
4.2.11 Prm 151
4.2.12 Gbt 440
4.2.13 Pbi4050
4.2.13.2 Strategic Development
4.2.14 Sar156597
4.2.15 Bms 986036
4.3 Phase I
4.3.1 Peg-Fgf21
4.3.2 Iw001
4.3.3 Mmi-0100
4.3.4 Zl-2102
4.3.5 Aeol 10150
4.3.6 Cc-90001
4.3.7 Vismodegib
4.3.8 Sd-560
4.3.9 Gsk3008348
4.3.10 Omipalisib
4.3.11 (Pentoxifylline + Acetylcysteine)
4.3.12 Sm04646
4.4 Pre-Clinical
4.4.1 Mor107
4.4.2 Ibio-Cfb03
4.4.3 Hec585
4.4.4 Hc-016
4.4.5 Iva 337
4.4.6 Isth 1106
4.4.7 Kbp-7018
4.4.8 Spl-334
4.4.9 Spl-891
4.4.10 Rt234
4.4.11 Sting-Antagonists
4.4.12 Lti-03
4.4.13 Avß1 Integrin Program
4.4.14 Small Molecule To Target Integrin 2
4.4.15 C188-9
4.4.16 Pur1500
4.4.17 Msm-735
4.4.18 Pbi-4425
4.4.19 Ad-114
4.4.20 Neumomir
4.4.21 Samirna Prodrug
4.4.22 Cabiralizumab
4.4.23 Gr-Md-02
4.4.24 Gkt831
4.4.25 Olx-201
4.4.26 Hl-156Fib
4.4.27 Pbf-1129
4.4.28 P007
4.4.29 Rbm-005
4.4.30 Rbm-003
4.4.31 Rbm-006
4.4.32 Rbm-007
4.4.33 Rp-6503
4.4.34 Cm-101
4.4.35 Gbt-1118
4.4.36 Ktn-0158
4.4.37 St2001
4.4.38 Bot191
4.5 Discovery
4.5.1 Loxl2 Inhibitor
4.5.2 Small Molecule To Target Emt
4.5.3 Tgf-ß Related Target
4.5.4 Integrin Target 3
4.5.5 Drug For Idiopathic Pulmonary Fibrosis
4.5.6 P013
4.5.7 Small Molecule For Ipf

5. Swot Analysis Of Idiopathic Pulmonary Fibrosis Pipeline

6. Company Profiles And Strategic Developments
6.1 Key Company Profiles
6.1.1 Bristol-Myers Squibb Company
6.1.2 F. Hoffmann-La Roche Ltd.
6.1.3 Merck & Co., Inc.
6.1.4 Global Blood Therapeutics, Inc.
6.1.5 Asahi Kasei Corporation
6.1.6 Beijing Tide Pharmaceutical Co., Limited
6.1.6.1 Business Overview
6.1.6.2 Product And Service Offerings
6.1.7 Fibrogen, Inc.
6.1.8 Chong Kun Dang Pharmaceutical Corp.
6.1.9 Galapagos Nv
6.1.10 Kadmon Holdings, Inc.
6.1.11 Medicinova, Inc.
6.1.12 Promedior, Inc.

7. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/sjdmqs/global_idiopathic

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Respiratory Drugs, Respiratory Drugs